Fate Therapeutics Inc. kicked off the trading day on 10/10/19 with a price increase of 2.79%, equivalent to $0.38 relative change for the day. Taking a more long-term approach, FATE had a 52-week range of $11.00 to $22.82. At the time of this article’s publishing, this stock is trading at $14.00 after starting the trading session at $13.65. At the time of writing, this stock’s 50-day Moving Average stands at $17.33, while the 200-day Moving Average of this stock is currently $17.45.
Currently, this company’s share volume is sitting at $1412004, but has maintained average daily volume of $767.15K. This stock has generated an average Year to Date volume of $740795, alongside an average 20-day volume of $832490. This publicly-traded company’s shares outstanding now amounts to $74.68 million, simultaneously with a float of $73.74 million. The organization now has a market capitalization sitting at $1.05 billion.
Fate Therapeutics Inc.(FATE) Ownership Data
Now let’s turn our focus to how large-scale investors are behaving with this stock. Fate Therapeutics Inc.’s current insider ownership accounts for 0.70%, in contrast to 85.60% institutional ownership. According to the most recent latest insider trade that took place on Sep 16 this organization’s Director bought 857,143 at the rate of 17.50, making the entire transaction hit 15,000,003 in total value, affecting insider ownership by 11,216,809. Preceding that transaction, on Aug 01 Company’s Director sold 30,866 at a price of 22.53, making the whole transaction’s value amount to 695,392. This particular insider is now the holder of 7,539 in total.
If we take a glance at the Ownership summary of Fate Therapeutics Inc.’s stock, Institutional holders make up 85.60% of its total stock ownership. All together, they are the legal holders of 74.68M shares. If we focus on the top 3 stockholders for this publicly-traded organization, Redmile Group LLC owns 11,216,809 shares, with Fidelity Management & Research Co. in 2nd place owning 6,872,683 shares and BlackRock Fund Advisors in third place with total ownership of 4,210,637 shares.
Fate Therapeutics Inc. (FATE) Earnings and Revenue Data
In the latest quarterly report that this company released, which was put into the public domain on 6/29/2019, the organization reported -$0.36 earnings per share (EPS) for the three-month period, surpassing the consensus estimate (set at -$0.33) by -$0.03.
This company achieved a net margin of -934.7 while generating a return on equity of -57.65. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.39 per share during the current fiscal year.
Fate Therapeutics Inc.’s EPS decrease for this current 12-month fiscal period is -15.80%, and is forecasted to reach -1.58 in the upcoming year.
Additional Trading Performance Indicators
Now turning our attention to the current performance indicators for Fate Therapeutics Inc., this organization’s Quick Ratio in the last reported quarter now stands at 5.60. The company has managed to achieve an average true range (ATR) of 1.01. Alongside those, its Beta score is 1.82.
Another valuable indicator worth considering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 129.08 for this organization. Plus, this company’s price to book ratio for the last three-month fiscal period reported is 7.14, whereas its price to cash per share for the last quarter landed at 2.17.
In the same vein, FATE’s Diluted EPS (Earnings per Share) trailing twelve months was posted at -1.22, a figure that is expected to reach -0.38 in the next reported quarter, and analysts expect it will be -1.58 at the market close of one year from today’s date.